1
|
Prensner JR, Enache OM, Luria V, Krug K, Clauser KR, Dempster JM, Karger A, Wang L, Stumbraite K, Wang VM, Botta G, Lyons NJ, Goodale A, Kalani Z, Fritchman B, Brown A, Alan D, Green T, Yang X, Jaffe JD, Roth JA, Piccioni F, Kirschner MW, Ji Z, Root DE, Golub TR. Noncanonical open reading frames encode functional proteins essential for cancer cell survival. Nat Biotechnol 2021; 39:697-704. [PMID: 33510483 PMCID: PMC8195866 DOI: 10.1038/s41587-020-00806-2] [Citation(s) in RCA: 62] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Accepted: 12/16/2020] [Indexed: 01/30/2023]
Abstract
Although genomic analyses predict many noncanonical open reading frames (ORFs) in the human genome, it is unclear whether they encode biologically active proteins. Here we experimentally interrogated 553 candidates selected from noncanonical ORF datasets. Of these, 57 induced viability defects when knocked out in human cancer cell lines. Following ectopic expression, 257 showed evidence of protein expression and 401 induced gene expression changes. Clustered regularly interspaced short palindromic repeat (CRISPR) tiling and start codon mutagenesis indicated that their biological effects required translation as opposed to RNA-mediated effects. We found that one of these ORFs, G029442-renamed glycine-rich extracellular protein-1 (GREP1)-encodes a secreted protein highly expressed in breast cancer, and its knockout in 263 cancer cell lines showed preferential essentiality in breast cancer-derived lines. The secretome of GREP1-expressing cells has an increased abundance of the oncogenic cytokine GDF15, and GDF15 supplementation mitigated the growth-inhibitory effect of GREP1 knockout. Our experiments suggest that noncanonical ORFs can express biologically active proteins that are potential therapeutic targets.
Collapse
Affiliation(s)
- John R. Prensner
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA.,Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,Division of Pediatric Hematology/Oncology, Boston Children’s Hospital, Boston, MA, 02115
| | - Oana M. Enache
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | - Victor Luria
- Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA
| | - Karsten Krug
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | - Karl R. Clauser
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | | | - Amir Karger
- IT-Research Computing, Harvard Medical School, Boston, MA, USA, 02115
| | - Li Wang
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | | | - Vickie M. Wang
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | - Ginevra Botta
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | | | - Amy Goodale
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | - Zohra Kalani
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | | | - Adam Brown
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | - Douglas Alan
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | - Thomas Green
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | - Xiaoping Yang
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | - Jacob D. Jaffe
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA.,Present address: Inzen Therapeutics, Cambridge, MA, 02139, USA
| | | | - Federica Piccioni
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA.,Present address: Merck Research Laboratories, Boston, MA, 02115, USA
| | - Marc W. Kirschner
- Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA
| | - Zhe Ji
- Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611,Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL 60628
| | - David E. Root
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA
| | - Todd R. Golub
- Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA.,Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,Division of Pediatric Hematology/Oncology, Boston Children’s Hospital, Boston, MA, 02115,Corresponding author: Address correspondence to: Todd R. Golub, MD, Chief Scientific Officer, Broad Institute of Harvard and MIT, Room 4013, 415 Main Street, Cambridge, MA, 02142, , Phone: 617-714-7050
| |
Collapse
|
2
|
Prensner J, Enache O, Luria V, Krug K, Clauser K, Dempster J, Karger A, Wang L, Stumbraite K, Wang V, Botta G, Lyons N, Goodale A, Kalani Z, Fritchman B, Brown A, Alan D, Green T, Yang X, Jaffe J, Roth J, Piccioni F, Kirschner M, Ji Z, Root D, Golub T. TBIO-26. NON-CANONICAL OPEN READING FRAMES ENCODE FUNCTIONAL PROTEINS ESSENTIAL FOR CANCER CELL SURVIVAL. Neuro Oncol 2020. [PMCID: PMC7715501 DOI: 10.1093/neuonc/noaa222.849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
The brain is the foremost non-gonadal tissue for expression of non-coding RNAs of unclear function. Yet, whether such transcripts are truly non-coding or rather the source of non-canonical protein translation is unknown. Here, we used functional genomic screens to establish the cellular bioactivity of non-canonical proteins located in putative non-coding RNAs or untranslated regions of protein-coding genes. We experimentally interrogated 553 open reading frames (ORFs) identified by ribosome profiling for three major phenotypes: 257 (46%) demonstrated protein translation when ectopically expressed in HEK293T cells, 401 (73%) induced gene expression changes following ectopic expression across 4 cancer cell types, and 57 (10%) induced a viability defect when the endogenous ORF was knocked out using CRISPR/Cas9 in 8 human cancer cell lines. CRISPR tiling and start codon mutagenesis indicated that the biological impact of these non-canonical ORFs required their translation as opposed to RNA-mediated effects. We functionally characterized one of these ORFs, G029442—renamed GREP1 (Glycine-Rich Extracellular Protein-1)—as a cancer-implicated gene with high expression in multiple cancer types, such as gliomas. GREP1 knockout in >200 cancer cell lines reduced cell viability in multiple cancer types, including glioblastoma, in a cell-autonomous manner and produced cell cycle arrest via single-cell RNA sequencing. Analysis of the secretome of GREP1-expressing cells showed increased abundance of the oncogenic cytokine GDF15, and GDF15 supplementation mitigated the growth inhibitory effect of GREP1 knock-out. Taken together, these experiments suggest that the non-canonical ORFeome is surprisingly rich in biologically active proteins and potential cancer therapeutic targets deserving of further study.
Collapse
Affiliation(s)
- John Prensner
- Boston Children’s Hospital/Dana-Farber Cancer Institute, Boston, MA, USA
- Broad Institute, Cambridge, MA, USA
| | | | | | | | | | | | | | - Li Wang
- Broad Institute, Cambridge, MA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Zhe Ji
- Harvard Medical School, Cambridge, MA, USA
| | | | - Todd Golub
- Boston Children’s Hospital/Dana-Farber Cancer Institute, Boston, MA, USA
- Broad Institute, Cambridge, MA, USA
| |
Collapse
|
3
|
Clohessy RM, Cohen DJ, Stumbraite K, Boyan BD, Schwartz Z. In vivo evaluation of an electrospun and 3D printed cellular delivery device for dermal wound healing. J Biomed Mater Res B Appl Biomater 2020; 108:2560-2570. [PMID: 32086992 DOI: 10.1002/jbm.b.34587] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Revised: 01/21/2020] [Accepted: 02/02/2020] [Indexed: 11/10/2022]
Abstract
Burns and chronic wounds are especially challenging wounds to heal. In efforts to heal these wounds, physicians often use autologous skin grafts to help restore mechanical and barrier functionality to the wound area. These grafts are, by nature, limited in availability. In an effort to provide an alternative, we have developed an electrospun wound dressing designed to incorporate into the wound with the option to deliver a cellular payload. Here, a blend of poly(glycolic acid) and poly(ethylene glycol) was electrospun as part of a custom fabrication method that incorporated 3D printed poly(vinyl alcohol) sacrificial elements. This preparation is unique compared to traditional electrospinning as sacrificial elements provide an internal void space for an injectable payload to be delivered to the wound site. When the construct was tested in vivo (full thickness excisional skin wounds), wound closure was slightly delayed by the presence of the scaffold in both normal and challenged wounds. Quality of healing was improved in normal wounds as measured by histomorphometrics when treated with the construct and exhibited increased neovascularization. Our results demonstrate that the extracellular matrix-like scaffold developed in this study is beneficial to healing of full thickness skin defects and may benefit challenged wounds.
Collapse
Affiliation(s)
- Ryan M Clohessy
- Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia
| | - David J Cohen
- Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia
| | - Karolina Stumbraite
- Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia
| | - Barbara D Boyan
- Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia.,Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Georgia
| | - Zvi Schwartz
- Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia.,Department of Periodontics, University of Texas Health Science Center at San Antonio, San Antonio, Texas
| |
Collapse
|
4
|
Bender S, Zhu C, Wang L, Rothberg M, Dempster J, Paolella B, Kocak M, Laird M, Rossen J, Stumbraite K, Bryan J, Wang V, Doench J, Vazquez F, Tsherniak A, Golub T, Roth J. Abstract 2690: Massively parallel multiplexed methods to screen hundreds of barcoded cancer cell line models with small molecules or genetic perturbations using next-generation sequencing. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-2690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Phenotypic screening is a valuable tool to identify compounds to treat cancer, but is limited as it is time and resource intensive to screen hundreds of cancer cell lines. In order to increase the throughput of phenotypic screening, we set out to expand and further develop the PRISM method (Profiling Relative Inhibition Simultaneously in Mixtures) [Yu et al., 2016]. PRISM is a method to barcode cell lines with a unique 24 nucleotide barcode and mix them together to screen simultaneously in a pool, decreasing the time and cost of screening. The previously described PRISM method was limited in that it used only 100 adherent cell lines of one cancer model context, it required the use of a highly specialized Luminex bead-based detection system, and it was only applicable to small molecule screening.
Here we report on the expansion of our barcoded cell line collection to 800 cancer cell lines of over 45 lineages, an improved method called PRISMseq using next-generation sequencing, and a novel method to perform genetic perturbations in 500 cancer cell lines simultaneously called PRISPR (PRISM/CRISPR). PRISMseq allows for assaying compound cell line sensitivity profiles in a large pool of hundreds of cell lines and detecting the DNA barcodes using next-generation sequencing (NGS). We recapitulate the known biology for established oncology drugs like the BRAF, EGFR, BCR-ABL and MDM2 inhibitor classes using this method with our cell line panel. We also further extended this method to be applicable to genetic perturbation using CRISPR/Cas9 knockout of individual genes concurrently in hundreds of cancer cell lines. We are able to recover expected biomarkers or genetic dependencies for our CRISPR/Cas9 validation reagents.
This expanded PRISM profiling approach increases statistical power due to the addition of cancer contexts in our cell line collection, and improves versatility by enabling the screening of both small molecules and genetic perturbations. We believe that this method has overcome the limitations of the original PRISM method. It has also overcome the limitations of phenotypic screening, as the resources required to screen hundreds of cell lines has been decreased by orders of magnitude.
Citation Format: Samantha Bender, Cong Zhu, Li Wang, Michael Rothberg, Joshua Dempster, Brenton Paolella, Mustafa Kocak, Massami Laird, Jordan Rossen, Karolina Stumbraite, Jordan Bryan, Vickie Wang, John Doench, Francisca Vazquez, Aviad Tsherniak, Todd Golub, Jennifer Roth. Massively parallel multiplexed methods to screen hundreds of barcoded cancer cell line models with small molecules or genetic perturbations using next-generation sequencing [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2690.
Collapse
Affiliation(s)
| | | | - Li Wang
- 1Broad Institute, Cambridge, MA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|